{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:07:50Z","timestamp":1758931670335,"version":"3.44.0"},"reference-count":63,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":56,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001215","name":"La Trobe University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001215","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000924","name":"Multiple Sclerosis Australia","doi-asserted-by":"publisher","award":["20\u2010032"],"award-info":[{"award-number":["20\u2010032"]}],"id":[{"id":"10.13039\/501100000924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Anim Models and Exp Med"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), exhibiting hallmarks of both inflammation and neurodegeneration and with limited treatment options. The intricate nature of MS pathophysiology and its variable progression pose severe challenges for the development of effective therapies. The experimental autoimmune encephalomyelitis (EAE) MS model, in its most common form, is an aggressive disease, which is not representative of the MS course and offers a limited time window for drug evaluation. This study aimed to generate an attenuated EAE variant, which extends the clinical testing window while preserving the high incidence of the standard EAE model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Components of the EAE induction protocol were titrated to develop a milder disease profile. In a subsequent drug trial using the MS medication fingolimod hydrochloride (FTY, Gilenya), the new variant was validated under prophylactic and therapeutic treatment regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The attenuated EAE variant retains the standard hallmarks of neuroinflammation and, crucially, significantly extends the time frame for clinical drug testing. Unlike the standard variant, where FTY efficacy could only be demonstrated by prophylactic treatment, the attenuated variant facilitated differentiation of drug effects by therapeutic treatment initiated early in the acute phase of disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The new EAE variant is suitable for use in preclinical assessment of candidate therapeutics and the identification of targetable molecular mechanisms underpinning disease development and progression. This study illustrates the importance of optimizing and refining the experimental tool to enhance the translational success of the candidate therapeutics for MS.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ame2.70071","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:15:35Z","timestamp":1758885335000},"page":"1428-1440","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Attenuating the experimental autoimmune encephalomyelitis model improves preclinical evaluation of candidate multiple sclerosis therapeutics"],"prefix":"10.1002","volume":"8","author":[{"given":"Vernise J. T.","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Rural Clinical Sciences and Holsworth Biomedical Research Centre La Trobe University  Bendigo Australia"},{"name":"La Trobe Institute for Molecular Science La Trobe University  Bundoora Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie J.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Psychology Counselling and Therapy, School of Psychology and Public Health, La Trobe University  Bundoora Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Stephen","family":"Penrose","sequence":"additional","affiliation":[{"name":"La Trobe Institute for Molecular Science La Trobe University  Bundoora Australia"},{"name":"Department of Biochemistry and Chemistry School of Agriculture, Biomedicine and Environment, La Trobe University  Bundoora Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coral","family":"Warr","sequence":"additional","affiliation":[{"name":"La Trobe Institute for Molecular Science La Trobe University  Bundoora Australia"},{"name":"Department of Biochemistry and Chemistry School of Agriculture, Biomedicine and Environment, La Trobe University  Bundoora Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-4069","authenticated-orcid":false,"given":"M. Cristina","family":"Keightley","sequence":"additional","affiliation":[{"name":"Department of Rural Clinical Sciences and Holsworth Biomedical Research Centre La Trobe University  Bendigo Australia"},{"name":"La Trobe Institute for Molecular Science La Trobe University  Bundoora Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0716-1291","authenticated-orcid":false,"given":"Jacqueline M.","family":"Orian","sequence":"additional","affiliation":[{"name":"La Trobe Institute for Molecular Science La Trobe University  Bundoora Australia"},{"name":"Department of Biochemistry and Chemistry School of Agriculture, Biomedicine and Environment, La Trobe University  Bundoora Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"9","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/acn3.50862","article-title":"Environmental and genetic risk factors for MS: an integrated review","volume":"6","author":"Waubant E","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.17712\/nsj.2015.4.20150357","article-title":"Update in vitamin D and multiple sclerosis","volume":"20","author":"Alharbi FM","year":"2015","journal-title":"Neurosciences (Riyadh)"},{"issue":"1","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40120-017-0086-4","article-title":"Vitamin D and multiple sclerosis: a comprehensive review","volume":"7","author":"Sintzel MB","year":"2018","journal-title":"Neurol Ther"},{"issue":"3","key":"e_1_2_12_5_1","first-page":"160","article-title":"Epstein\u2013Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"19","author":"Bjornevik K","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","article-title":"Epstein\u2013Barr virus and multiple sclerosis","volume":"21","author":"Soldan SS","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1756285611425694","article-title":"Smoking: effects on multiple sclerosis susceptibility and disease progression","volume":"5","author":"Wingerchuk DM","year":"2012","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp-2022-330848","article-title":"Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression","volume":"94","author":"Wu J","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"14","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1177\/13524585211001781","article-title":"Childhood obesity and multiple sclerosis: a mendelian randomization study","volume":"27","author":"Harroud A","year":"2021","journal-title":"Mult Scler J"},{"issue":"10","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/jamaneurol.2019.1997","article-title":"Association of Obesity with Multiple Sclerosis Risk and Response to first\u2010line disease modifying drugs in children","volume":"76","author":"Huppke B","year":"2019","journal-title":"JAMA Neurol"},{"issue":"9","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2022.101497","article-title":"Pathogenesis and management of multiple sclerosis revisited","volume":"69","author":"Shah A","year":"2023","journal-title":"Dis Mon"},{"issue":"3","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40120-022-00363-7","article-title":"A narrative review on axonal neuroprotection in multiple sclerosis","volume":"11","author":"Collongues N","year":"2022","journal-title":"Neurol Ther"},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1127704","article-title":"Immunomodulation\u2010a general review of the current state\u2010of\u2010the\u2010art and new therapeutic strategies for targeting the immune system","volume":"14","author":"Strzelec M","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"fcac094","DOI":"10.1093\/braincomms\/fcac094","article-title":"Tissue donations for multiple sclerosis research: current state and suggestions for improvement","volume":"4","author":"Vanderdonckt P","year":"2022","journal-title":"Brain Commun"},{"issue":"5","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.stem.2020.03.017","article-title":"Problems and pitfalls of identifying remyelination in multiple sclerosis","volume":"26","author":"Neumann B","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"8","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/nn.3168","article-title":"Animal models of multiple sclerosis: the good, the bad and the bottom line","volume":"15","author":"Ransohoff RM","year":"2012","journal-title":"Nat Neurosci"},{"issue":"7393","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1038\/nature11102","article-title":"Animal models: not close enough","volume":"484","author":"Rice J","year":"2012","journal-title":"Nature"},{"issue":"1","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12974-019-1501-9","article-title":"Differential neuro\u2010immune patterns in two clinically relevant murine models of multiple sclerosis","volume":"16","author":"DiSano KD","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"4","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00705-021-04968-5","article-title":"Viral mouse models used to study multiple sclerosis: past and present","volume":"166","author":"Libbey JE","year":"2021","journal-title":"Arch Virol"},{"issue":"2","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neulet.2009.02.004","article-title":"Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination","volume":"453","author":"Lindner M","year":"2009","journal-title":"Neurosci Lett"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0404.2008.01036.x","article-title":"The cuprizone model for demyelination","volume":"117","author":"Torkildsen \u00d8","year":"2008","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"e_1_2_12_22_1","first-page":"32","article-title":"Experimental models of demyelination and remyelination","volume":"35","author":"Torre\u2010Fuentes L","year":"2020","journal-title":"Neurolog\u00eda"},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106230","article-title":"An overall view of the most common experimental models for multiple sclerosis","volume":"184","author":"Dedoni S","year":"2023","journal-title":"Neurobiol Dis"},{"issue":"4","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu CS","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"1","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"19194","DOI":"10.1038\/s41598-019-55713-7","article-title":"Scoring disease in an animal model of multiple sclerosis using a novel infrared\u2010based automated activity\u2010monitoring system","volume":"9","author":"Shahi SK","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11481-025-10182-w","article-title":"A new perspective on mechanisms of neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis: the early and critical role of platelets in neuro\/axonal loss","volume":"20","author":"Orian JM","year":"2025","journal-title":"J Neuroimmune Pharmacol"},{"issue":"3","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nm1715","article-title":"Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells","volume":"14","author":"Stromnes IM","year":"2008","journal-title":"Nat Med"},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-1-0716-3585-8_15","article-title":"Active induction of a multiple sclerosis\u2010like disease in common laboratory mouse strains","volume":"2746","author":"Orian JM","year":"2024","journal-title":"Methods Mol Biol"},{"issue":"12","key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/jnr.21716","article-title":"Pertussis toxin induces angiogenesis in brain microvascular endothelial cells","volume":"86","author":"Lu C","year":"2008","journal-title":"J Neurosci Res"},{"issue":"1","key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0006-8993(99)01479-1","article-title":"Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood\u2013brain barrier without inducing reactive gliosis","volume":"832","author":"Rabchevsky AG","year":"1999","journal-title":"Brain Res"},{"issue":"12","key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1038\/cti.2016.82","article-title":"Primate autoimmune disease models; lost for translation?","volume":"5","author":"t\u2019 Hart BA","year":"2016","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jneuroim.2010.08.011","article-title":"Blood\u2013brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE","volume":"229","author":"Bennett J","year":"2010","journal-title":"J Neuroimmunol"},{"issue":"1","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12974-016-0757-6","article-title":"Cytokine and chemokine alterations in tissue, CSF, and plasma in early presymptomatic phase of experimental allergic encephalomyelitis (EAE), in a rat model of multiple sclerosis","volume":"13","author":"Borjini N","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"3","key":"e_1_2_12_34_1","first-page":"183","article-title":"T cell mediated pathogenesis in EAE: molecular mechanisms","volume":"38","author":"Kurschus FC","year":"2015","journal-title":"Biom J"},{"issue":"10","key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1007\/s12035-020-02017-x","article-title":"Seasonal variations in macrophages\/microglia underlie changes in the mouse model of multiple sclerosis severity","volume":"57","author":"\u00c1lvarez\u2010S\u00e1nchez N","year":"2020","journal-title":"Mol Neurobiol"},{"issue":"44","key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"27516","DOI":"10.1073\/pnas.2002817117","article-title":"Interactions between host genetics and gut microbiota determine susceptibility to CNS autoimmunity","volume":"117","author":"Montgomery TL","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awl083","article-title":"The value of animal models for drug development in multiple sclerosis","volume":"129","author":"Friese MA","year":"2006","journal-title":"Brain"},{"key":"e_1_2_12_38_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.639650","article-title":"Immunomodulation eliminates inflammation in the hippocampus in experimental autoimmune encephalomyelitis, but does not ameliorate anxiety\u2010like behavior","volume":"12","author":"Kocovski P","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1756285613488434","article-title":"Sex and gender issues in multiple sclerosis","volume":"6","author":"Harbo HF","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"e_1_2_12_40_1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8020162","article-title":"Platelet depletion is effective in ameliorating anxiety\u2010like behavior and reducing the pro\u2010inflammatory environment in the hippocampus in murine experimental autoimmune encephalomyelitis","volume":"8","author":"Kocovski P","year":"2019","journal-title":"J Clin Med"},{"key":"e_1_2_12_41_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.expneurol.2014.02.010","article-title":"Brain MRI of nasal MOG therapeutic effect in relapsing\u2010progressive EAE","volume":"255","author":"Levy Barazany H","year":"2014","journal-title":"Exp Neurol"},{"issue":"1","key":"e_1_2_12_42_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2008.09.014","article-title":"Upregulation of water channel aquaporin\u20104 in experimental autoimmune encephalomyeritis","volume":"276","author":"Miyamoto K","year":"2009","journal-title":"J Neurol Sci"},{"issue":"1","key":"e_1_2_12_43_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170825","article-title":"Prophylactic versus therapeutic fingolimod: restoration of presynaptic defects in mice suffering from experimental autoimmune encephalomyelitis","volume":"12","author":"Bonfiglio T","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"e_1_2_12_44_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneuroim.2010.10.006","article-title":"Experimental autoimmune encephalomyelitis (EAE) IN C57Bl\/6 mice is not associated with astrogliosis","volume":"232","author":"Pham H","year":"2011","journal-title":"J Neuroimmunol"},{"issue":"2","key":"e_1_2_12_45_1","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ajpath.2011.10.008","article-title":"Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood\u2010ocular barrier","volume":"180","author":"Copland DA","year":"2012","journal-title":"Am J Pathol"},{"issue":"7","key":"e_1_2_12_46_1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/jnen\/nly032","article-title":"Platelets drive inflammation and target gray matter and the retina in autoimmune\u2010mediated encephalomyelitis","volume":"77","author":"Sonia D'Souza C","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"e_1_2_12_47_1","doi-asserted-by":"crossref","first-page":"20, 1","DOI":"10.5334\/irsp.181","article-title":"A practical primer to power analysis for simple experimental designs","volume":"31","author":"Perugini M","year":"2018","journal-title":"Int. Rev. Soc. Psychol"},{"key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1037\/14805-020","volume-title":"Methodological issues and strategies in clinical research","author":"Ferguson CJ","year":"2016"},{"issue":"3","key":"e_1_2_12_49_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.neulet.2011.03.021","article-title":"Spinal cord histopathology of MOG peptide 35\u201355\u2010induced experimental autoimmune encephalomyelitis is time\u2010and score\u2010dependent","volume":"494","author":"Recks MS","year":"2011","journal-title":"Neurosci Lett"},{"issue":"4","key":"e_1_2_12_50_1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/glia.20935","article-title":"Characterization of relapsing\u2013remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL\/6 mice","volume":"58","author":"Berard JL","year":"2010","journal-title":"Glia"},{"issue":"1","key":"e_1_2_12_51_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ncl.2017.08.008","article-title":"The dynamics of the gut microbiome in multiple sclerosis in relation to disease","volume":"36","author":"Mowry EM","year":"2018","journal-title":"Neurol Clin"},{"issue":"6","key":"e_1_2_12_52_1","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.cmet.2018.05.006","article-title":"Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota","volume":"27","author":"Cignarella F","year":"2018","journal-title":"Cell Metab"},{"issue":"4","key":"e_1_2_12_53_1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1189\/jlb.0208133","article-title":"Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis","volume":"84","author":"Piccio L","year":"2008","journal-title":"J Leukoc Biol"},{"issue":"1","key":"e_1_2_12_54_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms11541","article-title":"Experimental priming of encephalitogenic Th1\/Th17 cells requires pertussis toxin\u2010driven IL\u20101\u03b2 production by myeloid cells","volume":"7","author":"Ronchi F","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"e_1_2_12_55_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.04.009","article-title":"Exogenous IL\u201012 suppresses experimental autoimmune encephalomyelitis (EAE) by tuning IL\u201010 and IL\u20105 levels in an IFN\u2010\u03b3\u2010dependent way","volume":"176","author":"Berghmans N","year":"2006","journal-title":"J Neuroimmunol"},{"issue":"4","key":"e_1_2_12_56_1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.4049\/jimmunol.174.4.1938","article-title":"High incidence of spontaneous disease in an HLA\u2010DR15 and TCR transgenic multiple sclerosis model","volume":"174","author":"Ellmerich S","year":"2005","journal-title":"J Immunol"},{"key":"e_1_2_12_57_1","first-page":"67","volume-title":"Methods in Cell Biology","author":"Nissen JC","year":"2022"},{"issue":"4","key":"e_1_2_12_58_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/08916934.2014.987344","article-title":"Deletion of IL\u20104R \u03b1 in the BALB\/c mouse is associated with altered lesion topography and susceptibility to experimental autoimmune encephalomyelitis","volume":"48","author":"Orian JM","year":"2015","journal-title":"Autoimmunity"},{"issue":"4","key":"e_1_2_12_59_1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/eji.1830250419","article-title":"Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL\/J mice by myelin oligodendrocyte glycoprotein (MOG)\u2010derived peptide: preliminary analysis of MOG T cell epitopes","volume":"25","author":"Rosbo NK","year":"1995","journal-title":"Eur J Immunol"},{"issue":"2","key":"e_1_2_12_60_1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s004019900163","article-title":"A neuropathological analysis of experimental autoimmune encephalomyelitis with predominant brain stem and cerebellar involvement and differences between active and passive induction","volume":"100","author":"Muller DM","year":"2000","journal-title":"Acta Neuropathol"},{"issue":"1","key":"e_1_2_12_61_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jneuroim.2014.08.307","article-title":"Treatment with FTY\u2010720 reverses social recognition deficits without affecting clinical scores or impaired motor performance in EAE in SJL mice","volume":"275","author":"De Bruin NMWJ","year":"2014","journal-title":"J Neuroimmunol"},{"issue":"10","key":"e_1_2_12_62_1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/nm1664","article-title":"LINGO\u20101 antagonist promotes spinal cord remyelination and axonal integrity in MOG\u2010induced experimental autoimmune encephalomyelitis","volume":"13","author":"Mi S","year":"2007","journal-title":"Nat Med"},{"issue":"5","key":"e_1_2_12_63_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001037","article-title":"Dimethyl fumarate treatment in patients with primary progressive multiple sclerosis: a randomized, controlled trial","volume":"8","author":"H\u00f8jsgaard Chow H","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"e_1_2_12_64_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ncl.2017.08.011","article-title":"New advances in disease\u2010modifying therapies for relapsing and progressive forms of multiple sclerosis","volume":"36","author":"Vidal\u2010Jordana A","year":"2018","journal-title":"Neurol Clin"}],"container-title":["Animal Models and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ame2.70071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:15:44Z","timestamp":1758885344000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ame2.70071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/ame2.70071"],"URL":"https:\/\/doi.org\/10.1002\/ame2.70071","archive":["Portico"],"relation":{},"ISSN":["2576-2095","2576-2095"],"issn-type":[{"value":"2576-2095","type":"print"},{"value":"2576-2095","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2024-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}